A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250).

ABSTRACT:

Background

Small-cell lung cancer (SCLC) is characterized by high genomic instability. Proteins involved in maintaining genomic stability, such as ataxia telangiectasia and Rad3-related (ATR) and topoisomerase 1, are promising therapeutic targets in SCLC. Berzosertib, a highly potent, selective, intravenously administered ATR inhibitor, has demonstrated promising antitumor activity in patients with platinum-resistant SCLC.

Materials and methods

This phase II, multicenter, open-label, single-arm study (NCT04768296) included patients with relapsed platinum-resistant SCLC who received berzosertib (210 mg/m² on days 2, 5) and topotecan (1.25 mg/m² on days 1-5) intravenously in 21-day cycles until disease progression. Primary endpoints were objective respons

SUBMITTER: Navarro A 

PROVIDER: S-EPMC12794503 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature